Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma

被引：25

作者：

He, Qing ^{[1
]}

Liu, Yang ^{[1
]}

Zou, Qing ^{[1
]}

Guan, Yong-Song ^{[1
]}

机构：

[1] Sichuan Univ, W China Hosp, Dept Oncol, Chengdu 610041, Sichuan Prov, Peoples R China

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2011年 / 17卷 / 18期

关键词：

Hepatocellular carcinoma; H101; Transcatheter arterial chemoembolization; Therapy; PHASE-II TRIAL; REPLICATING ADENOVIRUS; NECK-CANCER; ONYX-015; HEAD;

D O I：

10.3748/wjg.v17.i18.2353

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Transcatheter arterial chemoembolization (TACE) has become the standard treatment modality for unresectable hepatocellular carcinoma (HCC). Nonetheless, the clinical outcomes in patients with unresectable HCC are often unsatisfactory, especially in those with recurrent HCC. H101, an E1B gene deleted adenovirus, is known to have a significant antitumor activity. In addition, local injection of H101 can enhance the effect of antitumor therapies (chemotherapy and radiotherapy). Transarterial H101 gene injection in combination with TACE may help to control refractory and recurrent HCC. In this study, we report a 55-year-old patient with recurrent HCC which was treated with transarterial injection of H101 in combination with TACE, leading to a good clinical prognosis of the patient. (C) 2011 Baishideng. All rights reserved.

引用

收藏

页码：2353 / 2355

页数：3

相关论文

共 11 条

[1]

Multigene expression from a replicating adenovirus using native viral promoters [J].

Bauzon, M ;

Castro, D ;

Karr, M ;

Hawkins, LK ;

Hermiston, TW .

MOLECULAR THERAPY, 2003, 7 (04) :526-534

[2]

Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and-2 [J].

Benedict, CA ;

Norris, PS ;

Prigozy, TI ;

Bodmer, JL ;

Mahr, JA ;

Garnett, CT ;

Martinon, F ;

Tschopp, J ;

Gooding, LR ;

Ware, CF .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (05) :3270-3278

[3]

Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer [J].

Hamid, O ;

Varterasian, ML ;

Wadler, S ;

Hecht, JR ;

Benson, A ;

Galanis, E ;

Uprichard, M ;

Omer, C ;

Bycott, P ;

Hackman, RC ;

Shields, AF .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1498-1504

[4]

Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes [J].

Hermiston, TW ;

Kuhn, I .

CANCER GENE THERAPY, 2002, 9 (12) :1022-1035

[5]

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [J].

Khuri, FR ;

Nemunaitis, J ;

Ganly, I ;

Arseneau, J ;

Tannock, IF ;

Romel, L ;

Gore, M ;

Ironside, J ;

MacDougall, RH ;

Heise, C ;

Randlev, B ;

Gillenwater, AM ;

Bruso, P ;

Kaye, SB ;

Hong, WK ;

Kirn, DH .

NATURE MEDICINE, 2000, 6 (08) :879-885

[6]

Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015):: results of Phase I and II trials [J].

Kirn, D .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (03) :525-538

[7]

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival [J].

Llovet, JM ;

Bruix, J .

HEPATOLOGY, 2003, 37 (02) :429-442

[8]

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial [J].

Llovet, JM ;

Real, MI ;

Montaña, X ;

Planas, R ;

Coll, S ;

Aponte, J ;

Ayuso, C ;

Sala, M ;

Muchart, J ;

Solà, R ;

Rodés, J ;

Bruix, J .

LANCET, 2002, 359 (9319) :1734-1739

[9]

Viral oncolysis [J].

Mullen, JT ;

Tanabe, KK .

ONCOLOGIST, 2002, 7 (02) :106-119

[10]

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer [J].

Nemunaitis, J ;

Khuri, F ;

Ganly, I ;

Arseneau, J ;

Posner, M ;

Vokes, E ;

Kuhn, J ;

McCarty, T ;

Landers, S ;

Blackburn, A ;

Romel, L ;

Randlev, B ;

Kaye, S ;

Kirn, D .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :289-298